Merck & Co./MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Merck & Co.
Ticker
MRK
Sector
Healthcare
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Rahway, United States
Employees
71,000
Website
www.merck.com
Merck & Co. Metrics
BasicAdvanced
$324B
Market cap
142.64
P/E ratio
$0.90
EPS
0.40
Beta
$2.96
Dividend rate
2.31%
Dividend yield
Price and volume
Market cap
$324B
Beta
0.4
Dividend rate
$2.96
Financial strength
Current ratio
1.253
Quick ratio
0.725
Long term debt to equity
77.038
Total debt to equity
96.368
Dividend payout ratio (TTM)
327.06%
Interest coverage (TTM)
14.52%
Management effectiveness
Return on assets (TTM)
10.26%
Return on equity (TTM)
5.31%
Valuation
Price to earnings (TTM)
142.64
Price to revenue (TTM)
5.28
Price to book
8.62
Price to tangible book (TTM)
201.06
Price to free cash flow (TTM)
29.38
Dividend yield (TTM)
2.31%
Growth
Revenue change (TTM)
6.11%
Earnings per share change (TTM)
-82.49%
3-year revenue growth
13.63%
3-year earnings per share growth
-31.33%
3-year dividend per share growth
6.08%
What the Analysts think about Merck & Co.
Analyst Ratings
Majority rating from 28 analysts.
Merck & Co. Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$16B
7.83%
Net income
$4.8B
-488.42%
Profit margin
30.18%
-460.14%
Merck & Co. Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.06
$2.13
$0.03
$2.07
-
Expected
-$2.18
$1.95
-$0.11
$1.88
$2.14
Surprise
-5.39%
9.17%
-127.48%
10.40%
-
Merck & Co. News
AllArticlesVideos
Merck stops skin cancer combination therapy testing in late-stage study
Reuters·2 months ago
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
Business Wire·2 months ago
5 April Quality Dividend Growth Stock Raises
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
Jul
8
Merck & Co.
Dividend·Payment
$0.77
Per share
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $324B as of July 03, 2024.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 142.64 as of July 03, 2024.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of July 03, 2024, the dividend rate is $2.96 and the yield is 2.31%. Merck & Co. has a payout ratio of 327.06% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment is scheduled for July 08, 2024.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Merck & Co. stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.